Incyte Corporation

Equities

INCY

US45337C1027

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-22 pm EST			5-day change	1st Jan Change
105.06 ^USD	+0.37%		-0.17%	+6.37%

Jan. 20	RBC Raises Price Target on Incyte to $95 From $92, Keeps Sector Perform Rating	MT
Jan. 20	Wells Fargo Downgrades Incyte to Equalweight From Overweight, Adjusts PT to $107 From $116	MT

Transcript : Incyte Corporation Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 11

Published on 12/02/2025 at 12:35 pm EST - Modified on 12/02/2025 at 02:05 pm EST

S&P Capital IQ

Presenter Speech
David Lebowitz (Analysts)

Okay. All right. Let's get started with the next session of Citi's Global Healthcare Conference. It's my great pleasure to have with me the senior management

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Incyte Corporation

Jan. 20	RBC Raises Price Target on Incyte to $95 From $92, Keeps Sector Perform Rating	MT
Jan. 20	Wells Fargo Downgrades Incyte to Equalweight From Overweight, Adjusts PT to $107 From $116	MT
Jan. 16	Guggenheim Adjusts Price Target on Incyte to $130 From $125, Maintains Buy Rating	MT
Jan. 15	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
Jan. 13	TD Cowen Adjusts Price Target on Incyte to $128 From $101, Maintains Buy Rating	MT
Jan. 12	Incyte Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 08:15 AM
Jan. 08	Incyte Insider Sold Shares Worth $1,184,064, According to a Recent SEC Filing	MT
Jan. 08	Goldman Sachs Adjusts Price Target on Incyte to $90 From $80, Maintains Neutral Rating	MT
Jan. 08	RBC Raises Price Target on Incyte to $92 From $84, Keeps Sector Perform Rating	MT
Jan. 07	Palvella Therapeutics, Inc. Appoints Vimal Patel as Senior Vice President of Medical Affairs	CI
Jan. 06	Morgan Stanley Adjusts Price Target on Incyte to $94 From $92, Maintains Equalweight Rating	MT
Jan. 05	Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as First-Line Treatment for Diffuse Large B-Cell Lymphoma	CI
Jan. 05	Incyte Says Phase 3 Study of Tafasitamab for Large B-Cell Lymphoma Treatment Met Primary Endpoint	MT
Jan. 05	Incyte announces positive topline results from study of tafasitamab	RE
Jan. 05	Incyte's blood cancer therapy slows disease progression in trial	RE
Dec. 24	Truist Adjusts Price Target on Incyte to $103 From $93, Maintains Hold Rating	MT
Dec. 22	Incyte Says Its Cancer Drug Has Received Approval in Japan for Follicular Lymphoma	MT
Dec. 19	S&P 500 Posts Slight Weekly Gain, Led by Consumer Discretionary	MT
Dec. 17	Incyte announces European Commission approval of Minjuvi (tafasitamab)	RE
Dec. 17	Incyte Announces European Commission Approval of Minjuvi (Tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma	CI
Dec. 17	Incyte Says European Commission Approves Minjuvi Combination Therapy for Follicular Lymphoma	MT
Dec. 15	Incyte Corporation Presents at ESMO Congress 2025, Oct-17-2025 through Oct-21-2025
Dec. 12	Incyte Insider Sold Shares Worth $554,965, According to a Recent SEC Filing	MT
Dec. 12	Incyte Corporation Announces Resignation of Hervé Hoppenot from Board of Directors, Effective December 12, 2025	CI
Dec. 11	Incyte's Blood Cancer Drug Program 'Looks Very Viable' Amid Development Challenges, RBC Says	MT